EichorEICHOR
Location: Altenburg Synced from ClinicalTrials.gov · August 09, 2026

Clinical studies recruiting near Altenburg

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of
Phase N/A · Klinikum Altenburger Land · Goethe University · NCT02872987A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING
Phase N/A · Private Practice - Dr. Thomas Kupka /ID# 273631 · AbbVie · NCT06712628NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care
Phase N/A · Research Site · AstraZeneca · NCT07424261Investigation of Fixed Triple Inhaled Combination in Asthmatic Patients, in a Real-life Setting
Phase N/A · Chiesi Hungary Ltd. · NCT06678191Optimizing Reperfusion to Improve Outcomes and Neurologic Function
Phase 2/Phase 3 · Corxel Investigational Site · Corxel Pharmaceuticals · NCT06990867Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Dee
Phase 3 · Anthos Investigative Site 7006 · Anthos Therapeutics, Inc. · NCT05712200Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease o
Phase 3 · Clinical Trial Site · Alnylam Pharmaceuticals · NCT07181109A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
Phase 3 · Generate Biomedicines · NCT07276724A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
Phase N/A · Novartis Investigative Site · Novartis Pharmaceuticals · NCT05344469A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
Phase N/A · Klinikum Altenburger Land GmbH · argenx · NCT06298565Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcer
Phase N/A · Klinikum Altenburger Land /ID# 283912 · AbbVie · NCT06764706Safety and Efficacy of hUC-MSC for the Treatment of Cartilage Damage in the Knee Joint
Phase 1/Phase 2 · Klinikum Altenburger Land, Klinik für Orthopädie und Unfallc · BIONCaRT GmbH · NCT06981741A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Phase 2 · Pfizer · NCT06977581A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a
Phase 3 · Boehringer Ingelheim · NCT06935370Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)
Phase N/A · Klinikum Altenburger Land GmbH · Technische Universität Dresden · NCT03188874A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D
Phase 3 · AstraZeneca · NCT06878261ITP Registry and Accompanying Biospecimen Collection
Phase N/A · Klinikum Altenburger Land GmbH, Klinik für Innere Medizin/Hä · Jena University Hospital · NCT05152238A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease
Phase 1/Phase 2 · Clinic Altenburger Land GmbH · NSC-Therapeutics · NCT06995573An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
Phase N/A · Private Practice - Dr. Thomas Kupka /ID# 276236 · AbbVie · NCT06764693Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Phase 3 · Klinikum Altenburger Land GmbH · Pharmazz, Inc. · NCT05691244
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.